… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … offering, ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same … to fund its clinical trials, ongoing research and development activities and for working capital and other …
… Chief Scientific Officer Proven leader with deep worldwide ophthalmology experience, including multiple approvals … MD, who is departing ProQR. Dr. Shams brings to ProQR deep ophthalmology, scientific and research management experience, … as Senior Corporate Officer, Head of Global Research and Development and Chief Scientific Officer at Santen, a global …
… PQ-110-001 Phase 1/2 trial PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) … and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Patients … of visual function and retinal structure through ophthalmic endpoints, such as visual acuity (BCVA), mobility …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of … proceeds from the offering to fund ongoing research and development activities and for working capital and other …
… lives through transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today … led to approx. 50% editing in liver of mice. New optimizations are being evaluated (not disclosed in the … prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing …
… ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering … existing cash and cash equivalents, to advance clinical development of its product candidates, to progress its other …
… oligonucleotide QR-110 for treatment of inherited retinal dystrophy in adults and children with LCA10 Presenter : David … Poster title: Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Poster #: 29 … orphan drug designation in the United States and the European Union and received fast-track designation by the …
… 1b safety, tolerability and exploratory efficacy trial. Top-line data to be reported in mid-2017 Top-line data from a … of QR-010. A full study presentation is planned for the European Cystic Fibrosis Society Conference in June 2017. … QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a …
… - Nucleic Acids . LCA10 is a severe inherited retinal dystrophy associated with mutations in the CEP290 gene. … process by which QR-110 was identified as a potentially optimal therapeutic candidate using a patient-derived retinal … suggest the pharmacodynamic, pharmacokinetic and safety properties make QR-110 a promising candidate for the …
… at NACFC on October 27 Noreen Henig, M.D., Chief Development Officer of ProQR and John P. Clancy, M.D., … QR-010 is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a … orphan drug designation in the United States and the European Union. The QR-010 project has received funding from …
